Pasireotide treatment does not modify hyperglycemic and corticosterone acute restraint stress responses in rats

References

• Breitschaft, A., Hu, K., Hermosillo Reséndiz, K., Darstein, C., & Golor, G. (2014). Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study. Diabetes Research and Clinical Practice, 103, 458–465. doi:10.1016/j.diabres.2013.12.011
   PubMed Web of Science ®Google Scholar
• Busnardo, C., Tavares, R.F., Resstel, L.B., Elias, L.L., & Correa, F.M. (2010). Paraventricular nucleus modulates autonomic and neuroendocrine responses to acute restraint stress in rats. Autonomic Neuroscience, 158, 51–57. doi:10.1016/j.autneu.2010.06.003
   PubMed Web of Science ®Google Scholar
• Carvalho Miranda, P.A., Simões, E., Silva, A.C., de Oliveira Longo, J.R., Magalhães Madureira, M., Bastos Fóscolo, R., … Ribeiro-Oliveira, A. (2011). Angiotensin-converting enzyme inhibition changes the metabolic response to neuroglucopenic stress. Journal of the Renin Angiotensin Aldosterone System, 12, 153–160. doi:10.1177/1470320310390726
   PubMed Web of Science ®Google Scholar
• Castillo, V., Theodoropoulou, M., Stalla, J., Gallelli, M.F., Cabrera-Blatter, M.F., Haedo, M.R., … Arzt, E. (2011). Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease. Neuroendocrinology, 94, 124–136. doi:10.1159/000327429
   PubMed Web of Science ®Google Scholar
• Cescato, R., Loesch, K.A., Waser, B., Mäcke, H.R., Rivier, J.E., Reubi, J.C., & Schonbrunn, A. (2010). Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Molecular Endocrinology, 24, 240–249. doi:10.1210/me.2009-0321
   PubMed Web of Science ®Google Scholar
• Csaba, Z., Peineau, S., & Dournaud, P. (2012). Molecular mechanisms of somatostatin receptor trafficking. Journal of Molecular Endocrinology, 48, R1–12. doi:10.1530/JME-11-0121
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos, D., & Fleseriu, M. (2016). Pasireotide: a novel treatment for patients with acromegaly. Drug Design Development and Therapy, 10, 227–239. doi:10.2147/DDDT.S77999
   PubMed Web of Science ®Google Scholar
• Golor, G., Hu, K., Ruffin, M., Buchelt, A., Bouillaud, E., Wang, Y., & Maldonado, M. (2012). A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Design Development and Therapy, 6, 71–79. doi:10.2147/DDDT.S29125
   PubMed Web of Science ®Google Scholar
• Harms, P.G., & Ojeda, S.R. (1974). A rapid and simple procedure for chronic cannulation of the rat jugular vein. Journal of Applied Physiology, 36, 391–392. doi:10.1152/jappl.1974.36.3.391
   PubMed Web of Science ®Google Scholar
• Henry, R.R., Ciaraldi, T.P., Armstrong, D., Burke, P., Ligueros-Saylan, M., & Mudaliar, S. (2013). Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. Journal of Clinical Endocrinology & Metabolism, 98, 3446–3453. doi:10.1210/jc.2013-1771
   PubMed Web of Science ®Google Scholar
• Kao, Y.J., Ghosh, M., & Schonbrunn, A. (2011). Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Molecular Endocrinology, 25, 1040–1054. doi:10.1210/me.2010-0398
   PubMed Web of Science ®Google Scholar
• Kvetnansky, R., Sun, C.L., Lake, C.R., Thoa, N., Torda, T., & Kopin, I.J. (1978). Effect of handling and forced immobilization on rat plasma levels of epinephrine, norepinephrine, and dopamine-beta-hydroxylase. Endocrinology, 103, 1868–1874. doi:10.1210/endo-103-5-1868
   PubMed Web of Science ®Google Scholar
• Lesche, S., Lehmann, D., Nagel, F., Schmid, H.A., & Schulz, S. (2009). Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. Journal of Clinical Endocrinology & Metabolism, 94, 654–661. doi:10.1210/jc.2008-1919
   PubMed Web of Science ®Google Scholar
• Pacak, K., Palkovits, M., Yadid, G., Kvetnansky, R., Kopin, I.J., & Goldstein, D.S. (1998). Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. American Journal of Physiology, 275(4 Pt 2), R1247–R1255. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9756557
   Google Scholar
• Patel, Y.C. (1999). Somatostatin and its receptor family. Frontiers in Neuroendocrinology, 20, 157–198. doi:10.1006/frne.1999.0183
   PubMed Web of Science ®Google Scholar
• Pecori Giraldi, F., Pagliardini, L., Cassarino, M.F., Martucci, F., Sesta, A., Castelli, L., … Cavagnini, F. (2012). Stimulatory effect of SOM230 on human and rat adrenal corticosteroid secretion in vitro. General and Comparative Endocrinology, 178, 436–439. doi:10.1016/j.ygcen.2012.05.003
   PubMed Web of Science ®Google Scholar
• Pöll, F., Lehmann, D., Illing, S., Ginj, M., Jacobs, S., Lupp, A., … Schulz, S. (2010). Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Molecular Endocrinology, 24, 436–446. doi:10.1210/me.2009-0315
   PubMed Web of Science ®Google Scholar
• Reis, F.M., Ribeiro-de-Oliveira, A., Guerra, R.M., Reis, A.M., & Coimbra, C.C. (1996). Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress. Life Sciences, 58, 155–161. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8606624
   PubMed Web of Science ®Google Scholar
• Ribeiro-de-Oliveira, A., Guerra, R.M., Fóscolo, R.B., Marubayashi, U., Reis, A.M., & Coimbra, C.C. (1999). Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats. Journal of Endocrinology, 162, 237–242. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=ribeiro+de+oliveira+1999
   PubMed Web of Science ®Google Scholar
• Schmid, H.A., & Brueggen, J. (2012). Effects of somatostatin analogs on glucose homeostasis in rats. Journal of Endocrinology, 212, 49–60. doi:10.1530/JOE-11-0224
   PubMed Web of Science ®Google Scholar
• Schmid, H.A., Brue, T., Colao, A., Gadelha, M.R., Shimon, I., Kapur, K., … Fleseriu, M. (2016). Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine, 53, 210–219. doi:10.1007/s12020-016-0895-8
   PubMed Web of Science ®Google Scholar
• Silva, A.P., Schoeffter, P., Weckbecker, G., Bruns, C., & Schmid, H.A. (2005). Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. European Journal of Endocrinology, 153, R7–R10. doi:10.1530/eje.1.01998
   PubMed Web of Science ®Google Scholar
• Silverstein, J.M. (2016). Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary, 19, 536–543. doi:10.1007/s11102-016-0734-1
   PubMed Web of Science ®Google Scholar
• Stewart, L.Q., Roper, J.A., Young, W.S., O'Carroll, A.M., & Lolait, S.J. (2008). Pituitary-adrenal response to acute and repeated mild restraint, forced swim and change in environment stress in arginine vasopressin receptor 1b knockout mice. Journal of Neuroendocrinology, 20, 597–605. doi:10.1111/j.1365-2826.2008.01704.x
   PubMed Web of Science ®Google Scholar
• Sun, L., & Coy, D.H. (2016). Somatostatin and its Analogs. Current Drug Targets, 17, 529–537. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/ 26951062
   PubMed Web of Science ®Google Scholar
• Vachon, P., & Moreau, J.P. (2001). Serum corticosterone and blood glucose in rats after two jugular vein blood sampling methods: comparison of the stress response. Contemporary Topics in Laboratory Animal Science, 40, 22–24. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11560401
   PubMedGoogle Scholar
• Vergès, B. (2017). Effects of anti-somatostatin agents on glucose metabolism. Diabetes & Metabolism, 43, 411–415. doi:10.1016/j.diabet.2017.05.003
   PubMed Web of Science ®Google Scholar
• Weckbecker, G., Lewis, I., Albert, R., Schmid, H.A., Hoyer, D., & Bruns, C. (2003). Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Reviews Drug Discovery, 2, 999–1017. doi:10.1038/nrd1255
   PubMed Web of Science ®Google Scholar